Predictive Biomarkers for Targeted Therapies in Advanced NSCLC: EGFR mutations, EGFR Exon 20 Insertions, and HER2 Mutations

Download these slides from a live CCO Webinar for an overview of the latest clinical data informing optimal use of EGFR, EGFR ex20ins, and HER2 biomarkers to guide therapeutic decisions in advanced NSCLC, including updates from recent annual clinical oncology meetings.
Suresh S. Ramalingam, MD, FACP, FASCO
Lecia V. Sequist, MD, MPH
Format: Microsoft PowerPoint (.ppt)
File Size: 2.64 MB
Released: June 28, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Turning Point Therapeutics, Inc.

Related Content

Downloadable resource: current EGFR-targeted agents for advanced NSCLC with EGFR mutations, including exon 20 insertions, from Clinical Care Options (CCO)

Released: May 24, 2022

Downloadable resource on active research and ongoing clinical trials in EGFR-mutated NSCLC, from Clinical Care Options (CCO)

Released: May 24, 2022

Downloadable resource on best practices for molecular testing of targetable biomarkers in advanced NSCLC (May 2022), from Clinical Care Options (CCO)

Released: May 24, 2022

Clinical Care Options (CCO) commentary: Joel Neal, MD, discusses management of non-small-cell lung cancer (NSCLC) with uncommon EGFR mutations

Joel W. Neal, MD, PhD Released: May 20, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings